Maxim starts Ayala at buy; PT $22

Maxim Group initiated coverage of Ayala Pharmaceuticals (NASDAQ:AYLA) with a “buy” rating and $22 price target. The stock closed at $9 on Dec. 17.

Ayala is developing two gamma-secretase inhibitors – AL101 and AL102 – which were in-licensed from Bristol Myers, targeting the Notch signaling pathway, a well-documented driver of many cancers.

AL101 is being evaluated in adenoid cystic carcinoma in the Phase 2 ACCURACY study, and in triple-negative breast cancer in the Phase 2 TENACITY study. 

AL102 is being evaluated in desmoid tumors in the Phase 2/3 RINGSIDE study and in multiple myeloma. In addition, Ayala is on track to initiate another Phase 2 study of AL101, in T-cell acute lymphoblastic leukemia in 2022, writes analyst Naureen Quibria, Ph.D.  

“If the RINGSIDE study is positive for AL102, it may be registration-enabling,” Dr.  Quibria said. “AL101 also has the potential for an expedited regulatory path,” she added, noting that Ayala is expected to meet with the FDA at the end of the Phase 2 ACCURACY study in 2022. 

If several key catalysts in the next 12 months are positive, the “data should further de-risk each asset and shed greater light on their respective clinical profiles,” Dr. Quibria said. She said that with multiple differentiated studies to provide catalysts in 2022, and about $41-millon of cash on the balance sheet to provide a runway until 2023, and with a market cap of about $125-million, “we view the stock as undervalued.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.